Ascletis Pharma has returned for an $80m round that will fund the further clinical development of a potential treatment for non-alcoholic steatohepatitis symptoms.

Sagimet Biosciences, a US-based developer of treatments for fatty acid synthase, has raised $80m in crossover financing from investors including hepatitis C drug developer Ascletis Pharma.

An unnamed healthcare investment fund led the round, which also featured Kleiner Perkins, New Enterprise Associates (NEA), Rock Springs Capital, Altium Capital, HM Capital, Invus and PFM Health Sciences.

Sagimet, originally known as 3-V Biosciences, is working on a fatty acid synthase inhibitor that decreases liver fat and improves serum biomarkers of liver injury,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn